MatthewRWeirMD
Nephrology • Baltimore, MDProfessor, Internal Medicine, University of Maryland School of Medicine
Dr. Weir is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
N3W143 Nephrology, University of Maryland Medical Center
22 South Greene Street
Baltimore, MD 21201Phone+1 410-328-5720Fax+1 410-328-5685
Education & Training
Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 1981 - 1983
Yale-New Haven Medical Center (Waterbury)Residency, Internal Medicine, 1978 - 1981
University of Virginia School of MedicineClass of 1978
Certifications & Licensure
MD State Medical License 1983 - 2025
FL State Medical License 2013 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Long-term Follow-up of Spare the Nephron (STN) Patients Start of enrollment: 2010 Jun 01
- Safe Kidney Care Cohort Study Start of enrollment: 2011 Apr 01
- A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPatiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis.Andrew J S Coats, Stefan D Anker, Lars H Lund, Gerasimos Filippatos, Patrick Rossignol
JACC. Heart Failure. 2024-12-01 - 1 citationsPatiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia.Bertram Pitt, Stefan D Anker, Lars H Lund, Andrew J S Coats, Gerasimos Filippatos
Journal of the American College of Cardiology. 2024-10-01 - 7 citationsDCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.Yehuda Handelsman, John E Anderson, George L Bakris, Christie M Ballantyne, Deepak L Bhatt
Metabolism. 2024-10-01
Lectures
- Hypertension Challenges: Now that BP Targets Are Lower, How Do We Get There?American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/10/2019
- 4th Annual Essentials in Primary Care Summer Conference - Session 2Continuing Education Company Inc, Kiawah Island, South Carolina - 7/29/2013
- 4th Annual Essentials in Primary Care Summer Conference - Session 1Continuing Education Company Inc, Palm Coast, Florida - 7/22/2013
- Join now to see all
Press Mentions
Common Diuretic Pauses Atherosclerosis in CKD, T2DApril 15th, 2023- Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant HypertensionNovember 21st, 2022
- CareDx Committed to Delivering Clinical Innovation to the Transplant Patient and Physician CommunityNovember 11th, 2022
- Join now to see all
Grant Support
- Altold - Assessing Long Term Outcomes Of Living DonationNational Center For Research Resources2008–2009
- Lurds-Living Unrelated Kidney Donor And Sibling Follow-Up StudyNational Center For Research Resources2007
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
